Centogene

131 articles with Centogene

• CENTOGENE Reports Third Quarter 2021 Financial Results

  11/24/2021

  Centogene N.V. today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update.

• CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

  11/18/2021

  Centogene N.V. today announced that it will issue its financial results for the quarter ended September 30, 2021, on Wednesday, November 24, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CET / 8 a.m. ET that day.

• CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

  11/4/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it has expanded its partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study

  10/28/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that the first patient has been enrolled in the international EFRONT Study, an observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.

• Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

  10/6/2021

  Twist Bioscience Corporation and Centogene N.V. today announced that they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

• CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

  10/6/2021

  Centogene N.V. and Twist Bioscience Corporation announced today that they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

• CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects

  9/29/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the publication of results from a ground-breaking global genetic study in the New England Journal of Medicine, including findings of a potential treatment of structural birth defects caused by specific gene alterations.

• CENTOGENE Reports Second Quarter 2021 Financial Results

  9/7/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced financial results for the second quarter ended June 30, 2021, and provided an update on recent business progress.

• CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021

  9/1/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will issue its financial results for the quarter ended June 30, 2021, on Tuesday, September 7, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day.

• CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development

  7/27/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the appointment of Dr. Patrice P. Denèfle as Chief Scientific Officer.

• CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

  6/25/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the voting results of the Company’s Annual General Meeting.

• CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event

  6/22/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, will hold its first Virtual Investor Event, presented by its newly formed executive team.

• CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor EventFurther signs of recovery in the core rare disease business

  6/16/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced financial results for the first quarter ended March 31, 2021.

• CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021

  6/9/2021

  Centogene N.V. today announced that it will issue its financial results for the quarter ended March 31, 2021, on Wednesday, June 16, 2021.

• CENTOGENE Announces Virtual Investor EventNew leadership team to present vision, strategy, and execution roadmap

  6/7/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will be holding a Virtual Investor Event on Tuesday, June 22, 2021, at 9:00 a.m. - 11:00 a.m. EDT / 3:00 p.m. - 5:00 p.m. CEST.

• CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

  6/2/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.

• CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution

  6/1/2021

  Life-long support with free-of-charge and proactive variant reclassification demonstrates unique commitment to improving the lives of patients with rare diseases

• CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer

  5/26/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the nomination of Rene Just as Chief Financial Officer, which will be proposed to the shareholders at the upcoming Annual General Meeting.

• CENTOGENE Extends Global Parkinson’s Disease Study

  5/10/2021

  Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD)